检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:贺琪[1] 皮先明[1] 石全[1] 李家文[2] 杨迎香 陈宏翔[2]
机构地区:[1]湖北省中医院皮肤科,武汉市430061 [2]华中科技大学同济医学院附属协和医院皮肤科,武汉市430022 [3]湖北省浠水县中医院皮肤科,438200
出 处:《实用医学杂志》2016年第6期900-903,共4页The Journal of Practical Medicine
基 金:国家自然科学基金资助项目(编号:81171495;81271765)
摘 要:目的:探讨micro RNA-155(mi R-155)在寻常型银屑病中的表达及意义。方法:采用Taq Man探针实时荧光定量聚合酶链式反应(q RT-PCR)检测35例寻常型银屑病患者皮损区(皮损组)和非皮损区(非皮损组)中的mi R-155表达水平,并与30例正常对照(对照组)进行比较,研究mi R-155含量与患者银屑病面积和严重程度指数(PASI)评分和白细胞介素-17A(IL-17A)含量之间的关系。结果:mi R-155和IL-17A在皮损组和非皮损组中的表达高于对照组,在皮损组中的表达高于非皮损组,差异均有统计学意义(均P<0.01);皮损组中,mi R-155和IL-17A含量分别与PASI评分呈显著正相关(均P<0.05),mi R-155和IL-17A含量之间亦存在显著正相关(P<0.01)。结论:mi R-155的过表达与银屑病的发病有关,银屑病中mi R-155的过表达与Th17细胞的功能亢进有关。Objective Toexplore the expression and significance of micro RNA-155(mi R-155) in psoriasis vulgaris. Methods Areal-time quantitative reverse transcription polymerase chain reaction(q RT-PCR)method with Taq Man probe technology was performed to detect mi R-155 expression in skin lesion area and nonskinlesionalarea of 35 patients with psoriasis vulgaris, compared with that of 30 normal controls. The correlations among mi R-155 expression, psoriasis area and severity index(PASI) score and Interleukin-17A(IL-17A)expression were studied. Results The expressions of mi R-155 and IL-17 A in lesional and non-lesionalgroups were higher than that of control group(all P〈0.01). Also expressions in lesional skin were higher than nonlesional skin(both P〈0.01). In skin lesion group, significant positive correlations existed betweenmi R-155 or IL-17 A expression and PASI score as well as mi R-155 and IL-17 A expression(all P〈0.05). Conclusions Upexpression of mi R-155 was relevant to psoriasis development, which is related withthe hyperfunctionof Th17 cells in psoriasis.
关 键 词:MIR-155 寻常型银屑病 TAQMAN探针 白细胞介素-17
分 类 号:R758.63[医药卫生—皮肤病学与性病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117